GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » EV-to-EBITDA

Rhythm Biosciences (ASX:RHY) EV-to-EBITDA : -3.49 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rhythm Biosciences's enterprise value is A$23.23 Mil. Rhythm Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.66 Mil. Therefore, Rhythm Biosciences's EV-to-EBITDA for today is -3.49.

The historical rank and industry rank for Rhythm Biosciences's EV-to-EBITDA or its related term are showing as below:

ASX:RHY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -84.61   Med: 0   Max: 0
Current: -3.49

ASX:RHY's EV-to-EBITDA is ranked worse than
100% of 115 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.24 vs ASX:RHY: -3.49

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-14), Rhythm Biosciences's stock price is A$0.084. Rhythm Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.030. Therefore, Rhythm Biosciences's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Rhythm Biosciences EV-to-EBITDA Historical Data

The historical data trend for Rhythm Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences EV-to-EBITDA Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial -1.59 -27.32 -21.43 -7.58 -2.23

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.43 - -7.58 - -2.23

Competitive Comparison of Rhythm Biosciences's EV-to-EBITDA

For the Diagnostics & Research subindustry, Rhythm Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's EV-to-EBITDA falls into.



Rhythm Biosciences EV-to-EBITDA Calculation

Rhythm Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=23.231/-6.655
=-3.49

Rhythm Biosciences's current Enterprise Value is A$23.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rhythm Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (ASX:RHY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Rhythm Biosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.084/-0.030
=At Loss

Rhythm Biosciences's share price for today is A$0.084.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rhythm Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Rhythm Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences Business Description

Traded in Other Exchanges
N/A
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.

Rhythm Biosciences Headlines

No Headlines